Drugs / therapeutic allogeneic lymphocytes
last change Dec 2022 re-read 8 days ago

therapeutic allogeneic lymphocytes

Cell therapy

Developed for
leukemia · myelodysplastic syndrome · chronic lymphocytic leukemia/small lymphocytic lymphoma · Hodgkins lymphoma · plasma cell myeloma · plasma cell neoplasm · kidney cancer · Waldenstrom macroglobulinemia
+66 more · adult acute lymphoblastic leukemia · childhood acute myeloid leukemia · MALT lymphoma · mycosis fungoides and variants · nodal marginal zone B-cell lymphoma · splenic marginal zone lymphoma · acute myeloid leukemia with t(8;21)(q22;q22) translocation · acute myeloid leukemia, t(15;17)(q24;q21) · acute myeloid leukemia, t(16;16)(p13.1;q22) · adult T-cell leukemia/lymphoma · Burkitt lymphoma · extranodal nasal NK/T cell lymphoma · grade III lymphomatoid granulomatosis · graft versus host disease · hairy cell leukemia · hepatosplenic T-cell lymphoma · intraocular lymphoma · large-cell immunoblastic lymphoma · leukemia, myeloid, accelerated-phase · lymphoma · mantle cell lymphoma · peripheral T-cell lymphoma, not otherwise specified · primary cutaneous B-cell lymphoma · acute myeloid leukemia · acute myeloid leukemia with 11q23 abnormalities · acute myeloid leukemia, del(5q31-q32) · acute myeloid leukemia, inv(16)(p13.1;q22) · anaplastic large cell lymphoma · angioimmunoblastic T-cell lymphoma · blast phase chronic myelogenous leukemia, BCR-ABL1 positive · breast cancer · cancer · childhood acute lymphoblastic leukemia · childhood myelodysplastic syndrome · chronic myeloid leukemia · cutaneous melanoma · myelodysplastic/myeloproliferative neoplasm · small intestine lymphoma · T-cell large granular lymphocyte leukemia · testicular lymphoma · acquired polycythemia vera · acute myeloid leukemia with abnormal bone marrow eosinophils inv(16)(p13q22) or t(16;16)(p13;q22) · acute myeloid leukemia, FLT3 internal tandem duplication · acute myeloid leukemia, inv(3)(q21.3;q26.2) · acute myeloid leukemia, t(6;9)(p23;q34.1) · aplastic anemia · cervical cancer · childhood kidney cell carcinoma · chronic myelomonocytic leukemia · clear cell renal carcinoma · congenital amegakaryocytic thrombocytopenia · diffuse large B-cell lymphoma · follicular lymphoma · infectious disease · lymphoproliferative syndrome · myelodysplastic/myeloproliferative disease · myelofibrosis · myeloproliferative neoplasm · papillary renal cell carcinoma · Philadelphia-positive myelogenous leukemia · post-transplant lymphoproliferative disease · primary cutaneous T-cell non-Hodgkin lymphoma · renal cell carcinoma · severe congenital neutropenia · therapy related acute myeloid leukemia and myelodysplastic syndrome · vaginal cancer
Investigated by
National Cancer Institute (NCI) · Fred Hutchinson Cancer Center · University of California, San Francisco · National Heart, Lung, and Blood Institute (NHLBI) · Rutgers, The State University of New Jersey · University of Chicago
+20 more · University of Maryland, Baltimore · University of Medicine and Dentistry of New Jersey · AIDS Malignancy Consortium · Alliance for Clinical Trials in Oncology · Case Comprehensive Cancer Center · Eastern Cooperative Oncology Group · Fox Chase Cancer Center · Jonsson Comprehensive Cancer Center · Masonic Cancer Center, University of Minnesota · Milton S. Hershey Medical Center · Robert Lowsky · Rutgers Cancer Institute of New Jersey · SWOG Cancer Research Network · Sidney Kimmel Comprehensive Cancer Center at Thomas Jefferson University · University of California, San Diego · University of Colorado, Denver · University of Edinburgh · University of Southern California · University of Texas Southwestern Medical Center · Yale University

Trials 40

PhaseRegistry idDatesIndicationSponsorStatusOutcome
Phase 18 trials
Phase 1 NCT01523223 Jan 2012 → Sep 2016 Burkitt lymphoma, Hodgkins lymphoma, MALT lymphoma, Waldenstrom macroglobulinemia +19 Robert Lowsky Completed No outcome recorded
Phase 1 NCT00769613 Aug 2008 → Aug 2014 cancer Milton S. Hershey Medical Center Unknown No outcome recorded
Phase 1 NCT00295971 Apr 2005 → Dec 2011 congenital amegakaryocytic thrombocytopenia, leukemia, myelodysplastic syndrome, severe congenital neutropenia University of California, San Francisco Completed No outcome recorded
Phase 1 NCT00104975 Feb 2005 → May 2008 leukemia, lymphoma, myelodysplastic syndrome, myelodysplastic/myeloproliferative neoplasm Yale University Completed No outcome recorded
Phase 1 NCT00176475 Jan 2005 → Feb 2008 leukemia, plasma cell neoplasm University of Medicine and Dentistry of New Jersey Terminated No outcome recorded Stop: Enrollment
Phase 1 NCT00161187 May 2001 → Oct 2010 cancer University of Medicine and Dentistry of New Jersey Completed No outcome recorded
Phase 1 NCT00005946 Oct 2000 → Jun 2002 leukemia, myelodysplastic syndrome, plasma cell neoplasm University of Maryland, Baltimore Completed No outcome recorded
Phase 1 NCT00107354 Dec 1998 → Aug 2009 leukemia, myelodysplastic syndrome Fred Hutchinson Cancer Center Completed No outcome recorded
Phase 1/24 trials
Phase 1/2 NCT00248430 Aug 2003 → Jul 2007 graft versus host disease, leukemia, plasma cell neoplasm Fred Hutchinson Cancer Center Completed No outcome recorded
Phase 1/2 NCT00068718 May 2003 → Apr 2013 Hodgkins lymphoma, acute myeloid leukemia, adult acute lymphoblastic leukemia, blast phase chronic myelogenous leukemia, BCR-ABL1 positive +1 Fred Hutchinson Cancer Center Completed No outcome recorded
Phase 1/2 NCT00027547 Jul 2001 → Jul 2004 leukemia Fred Hutchinson Cancer Center Completed No outcome recorded
Phase 1/2 NCT00005851 Feb 2000 → Jul 2004 renal cell carcinoma Fred Hutchinson Cancer Center Completed No outcome recorded
Phase 222 trials
Phase 2 NCT02587871 Dec 2018 → Nov 2020 childhood acute myeloid leukemia University of Southern California Withdrawn No outcome recorded
Phase 2 NCT01839916 Apr 2013 → Aug 2018 Burkitt lymphoma, Hodgkins lymphoma, MALT lymphoma, T-cell large granular lymphocyte leukemia +31 University of Chicago Completed No outcome recorded
Phase 2 NCT01760655 Dec 2012 → Apr 2022 Hodgkins lymphoma, acquired polycythemia vera, acute myeloid leukemia, FLT3 internal tandem duplication, acute myeloid leukemia, inv(3)(q21.3;q26.2) +11 Sidney Kimmel Comprehensive Cancer Center at Thomas Jefferson University Completed No outcome recorded
Phase 2 NCT00853125 Feb 2009 → Feb 2014 kidney cancer Rutgers, The State University of New Jersey Terminated No outcome recorded Stop: Enrollment
Phase 2 NCT00274846 Mar 2005 → Jun 2008 leukemia Masonic Cancer Center, University of Minnesota Completed No outcome recorded
Phase 2 NCT00176501 Aug 2004 → Aug 2008 kidney cancer Rutgers, The State University of New Jersey Terminated No outcome recorded Stop: Enrollment
Phase 2 NCT00074269 Jul 2003 → Mar 2008 breast cancer University of California, San Diego Terminated No outcome recorded Stop: Enrollment
Phase 2 NCT00096161 May 2003 → Feb 2015 Hodgkins lymphoma, Philadelphia-positive myelogenous leukemia, Waldenstrom macroglobulinemia, acute myeloid leukemia +4 Fred Hutchinson Cancer Center Completed No outcome recorded
Phase 2 NCT00053014 Apr 2003 → Jun 2005 leukemia SWOG Cancer Research Network Terminated No outcome recorded Stop: Enrollment
Phase 2 NCT00027573 Oct 2001 → Jun 2006 kidney cancer Alliance for Clinical Trials in Oncology Completed No outcome recorded
Phase 31 trial
Phase 3 NCT00033475 Mar 2001 → ? lymphoproliferative syndrome University of Edinburgh Completed No outcome recorded
Phase not applicable4 trials
— NCT00301860 Jan 2003 → Mar 2007 leukemia, lymphoma University of California, San Francisco Terminated No outcome recorded
— NCT00005799 Nov 1999 → Jul 2002 Hodgkins lymphoma, MALT lymphoma, T-cell large granular lymphocyte leukemia, Waldenstrom macroglobulinemia +22 Fred Hutchinson Cancer Center Completed No outcome recorded
— NCT00296023 Jan 1999 → Jun 2007 leukemia, myelodysplastic syndrome, myeloproliferative neoplasm, plasma cell neoplasm University of California, San Francisco Completed No outcome recorded
— NCT00003196 Sep 1997 → Apr 2002 Burkitt lymphoma, MALT lymphoma, Waldenstrom macroglobulinemia, adult T-cell leukemia/lymphoma +19 Fred Hutchinson Cancer Center Completed No outcome recorded
Phase not stated1 trial
— NCT00547235 Sep 2007 → Dec 2012 infectious disease, precancerous condition Fred Hutchinson Cancer Center No longer available No outcome recorded
Comparator or background therapy14 trials
Phase 1 NCT00080925 Background Feb 2004 → Dec 2010 leukemia, myelodysplastic syndrome, myelodysplastic/myeloproliferative neoplasm, plasma cell neoplasm National Institutes of Health Clinical Center (CC) Completed No outcome recorded
Phase 1 NCT00003243 Background Jan 1998 → ? leukemia, lymphoma, myelodysplastic syndrome, myelodysplastic/myeloproliferative disease Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins Completed No outcome recorded
Phase 1/2 NCT00448357 Background Oct 2005 → Nov 2015 leukemia, myelodysplastic syndrome, myeloproliferative neoplasm, plasma cell neoplasm UNC Lineberger Comprehensive Cancer Center Completed No outcome recorded
Phase 1/2 NCT00245037 Background Jun 2005 → Aug 2015 leukemia, myelodysplastic syndrome, myelodysplastic/myeloproliferative neoplasm, plasma cell neoplasm +1 OHSU Knight Cancer Institute Completed No outcome recorded
Phase 1/2 NCT00281983 Background Jun 2000 → Jul 2010 B-cell chronic lymphocytic leukemia German CLL Study Group Completed No outcome recorded

Evidence & citations 5 cited values

Every value below carries the sentence it was read from. 54 sources stand behind the page.

FieldValueCited text
Known as therapeutic allogeneic lymphocytes ClinicalTrials.gov intervention name — accepted as the source's own label NCT00176475 ↗
53

NCT01118013 ↗

NCT00245037 ↗

NCT00003954 ↗

NCT00006233 ↗

NCT00068718 ↗

NCT00025519 ↗

NCT00066417 ↗

NCT00074269 ↗

NCT00027573 ↗

NCT00248430 ↗

Show 43 more sources

Known as donor lymphocyte infusion “Giving an infusion of the donor's T cells (donor lymphocyte infusion) after the transplant may help increase this effect.” NCT00296023 ↗
Action Deplete “donor white blood cells that have been treated in the laboratory to kill cells infected with Epstein-Barr virus” NCT00033475 ↗
Modality Cell therapy “Donor lymphocyte infusions or second unmodified allogeneic bone marrow transplantation without GM-CSF is considered in case of primary or secondary engraftment failure.” NCT00002778 ↗
Route Intravenous “Patients receive initial cell dose of donor lymphocytes (CD3+ cells) IV over 15-30 minutes” NCT00003153 ↗